Transient myeloproliferative disorder in children with Down syndrome: Clarity to this enigmatic disorder

British Journal of Haematology

Volumn 159, Issue 3, 2012, Pages 277-287

  Gamis, Alan S ^a   Smith, Franklin O ^b  

^a CHILDREN S MERCY HOSPITAL   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Down syndrome; GATA1; Leukaemia; Newborn; Transient Myeloproliferative Disorder

Indexed keywords

CD34 ANTIGEN; CYTARABINE; ERYTHROPOIETIN RECEPTOR; THROMBOPOIETIN RECEPTOR; TRANSCRIPTION FACTOR GATA 1;

ACUTE GRANULOCYTIC LEUKEMIA; ASCITES; BONE MARROW SUPPRESSION; CANCER RISK; CHILDHOOD DISEASE; CHOLESTASIS; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DOWN SYNDROME; DRUG SAFETY; DRUG TOLERABILITY; FETUS HYDROPS; GATA1 GENE; GENETIC ASSOCIATION; HEMATOLOGIC DISEASE; HEPATOMEGALY; HUMAN; INCIDENCE; KIDNEY FAILURE; MOLECULAR PATHOLOGY; MORTALITY; MUTATIONAL ANALYSIS; MUTATOR GENE; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PERICARDIAL EFFUSION; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SKIN INFILTRATE; SPLEEN DISEASE; TRANSIENT MYELOPROLIFERATIVE DISORDER;

CHILD; CHILD, PRESCHOOL; DOWN SYNDROME; HUMANS; INCIDENCE; LEUKEMIA; MYELOPROLIFERATIVE DISORDERS; RISK FACTORS;

EID: 84867439219     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12041     Document Type: Review

References (76)

1. Ahmed, M., Sternberg, A., Hall, G., Thomas, A., Smith, O., O'Marcaigh, A., Wynn, R., Stevens, R., Addison, M., King, D., Stewart, B., Gibson, B., Roberts, I. & Vyas, P. (2004) Natural history of GATA1 mutations in Down syndrome. Blood, 103, 2480-2489.
2. Alford, K.A., Reinhardt, K., Garnett, C., Norton, A., Bohmer, K., von Neuhoff, C., Kolenova, A., Marchi, E., Klusmann, J., Roberts, I., Hasle, H., Reinhardt, D. & Vyas, P. (2011) Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia. Blood, 118, 2222-2238.
3. Al-Kasim, F., Doyle, J.J., Massey, G.V., Weinstein, H.J. & Zipursky, A. (2002) Incidence and treatment of potentially lethal diseases in transient leukemia of Down syndrome: Pediatric Oncology Group study. Journal of Pediatric Hematology/Oncology, 24, 9-13.
4. Baum, R., Nash, P., Foster, J., Spader, M., Ratliff-Schaub, K. & Coury, D. (2008) Primary care of children and adolescents with Down syndrome: an update. Current Problems in Pediatric and Adolescent Health Care, 38, 241-261.
5. Becroft, D.M.O. & Zwi, L.J. (1990) Perinatal visceral fibrosis accompanying the megakaryoblastic leukemoid reaction of Down syndrome. Pediatric Pathology, 10, 397-406.
6. Bennett, J.M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D.A.G., Gralnick, H.R. & Sultan, C. (1985) Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). Annals of Internal Medicine, 103, 460-462.
7. Bernhard, W.G., Gore, I. & Kilby, R.A. (1951) Congenital leukemia. Blood, 6, 990-1001.
8. Brodeur, G.M., Dahl, G.V., Williams, D.L., Tipton, R.E. & Kalwinsky, D.K. (1980) Transient leukemoid reaction and trisomy 21 mosaicism in a phenotypically normal newborn. Blood, 55, 691-693.
9. Burch, J.M., Weston, W.L., Rogers, M. & Morelli, J.G. (2003) Cutaneous pustular leukemoid reactions in trisomy 21. Pediatric Dermatology, 20, 232-237.
10. Calligaris, R., Bottardi, S., Cogoi, S., Apezteguia, I. & Santoro, C. (1995) Alternative translation initiation site usage results in two functionally distinct forms of the GATA-1 transcription factor. Proceedings of the National Academy of Sciences of the United States of America, 92, 11598-11602.
11. Carmichael, C.L., Majewski, I.J., Alexander, W.S., Metcalf, D., Hilton, D.J., Hewitt, C.A. & Scott, H.S. (2009) Hematopoietic defects in the Ts1Cje mouse model of Down syndrome. Blood, 113, 1929-1937.
12. Castro-Malaspina, H., Rabellino, E.M., Yen, A., Nachman, R.L. & Moore, M.A. (1981) Human megakaryocyte stimulation of proliferation of bone marrow fibroblasts. Blood, 57, 781-787.
13. Centers for Disease Control and Prevention (CDC) (1994) Down syndrome prevalence at birth - United States, 1983-1990. Morbidity and Mortality Weekly Report, 43, 617-622.
14. Chou, S.T., Opalinska, J.B., Yao, Y., Fernandes, M.A., Kalota, A., Brooks, J.S., Choi, J.K., Gewirtz, A.M., Danet-Desnoyers, G., Nemiroff, R.L. & Weiss, M.J. (2008) Trisomy 21 enhances human fetal erythro-megakaryocytic development. Blood, 112, 4503-4506.
15. Conen, P.E. & Erkman, B. (1966) Combined mongolism and leukemia. American Journal of Diseases in Childhood, 112, 429-443.
16. Coulombel, L., Derycke, M., Villebal, J.L., Leonard, C., Breton-Gorius, J., Vial, M., Bourgeois, P. & Tchernia, G. (1987) Characterization of the blast cell population in two neonates with Down's syndrome and transient myeloproliferative disorder. British Journal of Haematology, 66, 69-76.
17. Crispino, J.D. (2005) GATA1 mutations in Down syndrome: implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia. Pediatric Blood & Cancer, 44, 40-44.
18. Cunniff, C., Frias, J.L., Kaye, C., Moeschler, J.B., Panny, S.R. & Trotter, T.L. (2001) Health supervision for children with Down syndrome. Pediatrics, 107, 442-449.
19. Dinulos, J.G., Hawkins, D.S., Clark, B.S. & Francis, J.S. (1997) Spontaneous remission of congenital leukemia. Journal of Pediatrics, 131, 300-303.
20. Gamis, A.S., Alonzo, T.A., Gerbing, R.B., Hilden, J.M., Sorrell, A.D., Sharma, M., Loew, T.W., Arceci, R.J., Barnard, D., Doyle, J., Massey, G., Perentesis, J., Ravindranath, Y., Taub, J. & Smith, F.O. (2011) Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971. Blood, 118, 6752-6759.
21. Girodon, F., Favre, B., Couillaud, G., Carli, P.M., Parmeland, C. & Maynadie, M. (2000) Immunophenotype of a transient myeloproliferative disorder in a newborn with trisomy 21. Cytometry, 42, 118-122.
22. Greene, M.E., Mundshau, G., Wechsler, J., McDevitt, M., Gamis, A., Karp, J., Gurbuxani, S., Arceci, R. & Crispino, J.D. (2003) Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome. Blood Cells, Molecules, and Diseases, 31, 351-356.
23. Gurbuxani, S., Vyas, P. & Crispino, J.D. (2004) Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. Blood, 103, 399-406.
24. Hattori, H., Matsuzaki, A., Suminoe, A., Ihara, K. & Nakayama, H. (2001) High expression of platelet-derived growth factor and transforming growth factor-B1 in blast cells from patients with Down syndrome suffering from transient myeloproliferative disorder and organ fibrosis. British Journal of Haematology, 115, 472-475.
25. Hayashi, Y., Eguchi, M., Sugita, K., Nakazawa, S., Sato, T., Kojima, S., Bessho, F., Konishi, S., Inaba, T., Hanada, R. & Yamamoto, K. (1988) Cytogenetic findings and clinical features in acute leukemia and transient myeloproliferative disorder in Down's syndrome. Blood, 72, 15-23.
26. Hayes, C., Johnson, Z., Thornton, L., Fogarty, J., Lyons, R., O'Connor, M., Delany, V. & Buckley, K. (1997) Ten-year survival of Down syndrome births. International Journal of Epidemiology, 26, 822-829.
27. Henry, E., Walker, D., Wiedmeier, S.E. & Christensen, R.D. (2007) Hematologic abnormalities during the first week of life among neonates with Down syndrome. American Journal of Medical Genetics. Part A, 143A, 42-50.
28. Hitzler, J.K., Cheung, J., Li, Y., Scherer, S.W. & Zipursky, A. (2003) GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood, 101, 4301-4304.
29. Honda, F., Punnett, H.H., Charney, E., Miller, G. & Theide, H.A. (1964) Serial cytogenetic and hematologic studies on a mongol with trisomy-21 and acute congenital leukemia. Journal of Pediatrics, 65, 880-887.
30. Isaacs, H. (2003) Fetal and neonatal leukemia. Journal of Pediatric Hematology/Oncology, 25, 348-361.
31. Kanezaki, R., Toki, T., Terui, K., Xu, G., Wang, R., Shimada, A., Hama, A., Kanegane, H., Kawakami, K., Endo, M., Hasegawa, D., Kogawa, K., Adachi, S., Ikeda, Y., Iwamoto, S., Taga, T., Kosaka, Y., Kojima, S., Hayashi, Y. & Ito, E. (2010) Down syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia. Blood, 116, 4631-4638.
32. Karandikar, N., Aquino, D., McKenna, R. & Kroft, S. (2001) Transient myeloproliferative disorder and acute myeloid leukemia in Down syndrome. American Journal of Clinical Pathology, 116, 204-210.
33. Klusmann, J.H., Creutzig, U., Zimmerman, M., Dworzak, M., Jorch, N., Langebrake, C., Pekrun, A., Macakova-Reinhardt, K. & Reinhardt, D. (2008) Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood, 111, 2991-2998.
34. Kojima, S., Matsuyama, T., Sato, T., Horibe, K., Konishi, S., Tsuchida, M., Hayashi, Y., Kigasawa, H., Akiyama, Y., Okamura, J., Nakahata, T., Bessho, F., Eguchi, M., Nakazawa, S. & Ueda, R. (1990) Down's syndrome and acute leukemia in children: an analysis of phenotype by use of monoclonal antibodies and electron microscopic platelet peroxidase reaction. Blood, 76, 2348-2353.
35. Krivit, W. & Good, R.A. (1957) Simultaneous occurrence of mongolism and leukemia. American Journal of Diseases of Children, 94, 289-293.
36. Kurahashi, H., Hara, J., Yumura-Yagi, K., Murayama, N., Inoue, M., Ishihara, S., Tawa, A., Okada, S. & Kawa-Ha, K. (1991) Monoclonal nature of transient abnormal myelopoiesis in Down's syndrome. Blood, 77, 1161-1163.
37. Langebrake, C., Creutzig, U. & Reinhardt, D. (2005) Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts. Klin Pädiatr, 217, 126-134.
38. Lewis, D. (1981) Association between megakaryoblastic leukaemia and Down syndrome. Lancet, 2, 695.
39. Malinge, S., Izraeli, S. & Crispino, J.D. (2009) Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. Blood, 113, 2619-2628.
40. Massey, G.V., Zipursky, A., Chang, M.N., Doyle, J.J., Nasim, S., Taub, J.W., Ravindranath, Y., Dahl, G. & Weinstein, H.J. (2006) A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481. Blood, 107, 4606-4613.
41. Miller, J.M., Sherrill, J.G. & Hathaway, W.E. (1967) Thrombocythemia in the myeloproliferative disorder of Down's syndrome. Pediatrics, 40, 847-850.
42. Miyauchi, J., Kawano, T., Tsunematsu, Y. & Shimizu, K. (1992) Unusual diffuse liver fibrosis accompanying transient myeloproliferative disorder in Down's syndrome: a report of four autopsy cases and proposal of a hypothesis. Blood, 80, 1521-1527.
43. Mundshau, G., Gurbuxani, S., Gamis, A.S., Greene, M.E., Arceci, R.J. & Crispino, J.D. (2003) Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood, 101, 4298-4300.
44. Muramatsu, H., Kato, K., Watanabe, N., Matsumoto, K., Nakamura, T., Horikoshi, Y., Mimaya, J., Suzuki, C., Hayakawa, M. & Kojima, S. (2008) Risk factors for early death in neonates with Down syndrome and transient leukaemia. British Journal of Haematology, 142, 610-615.
45. Nagao, T., Lamplin, B.C. & Hug, G. (1970) A neonate with Down's syndrome and transient abnormal myelopoiesis: serial blood and bone marrow studies. Blood, 36, 443-447.
46. Nakagawa, T., Nishida, H., Arai, T., Yamada, T., Fukuda, M. & Sakamoto, S. (1988) Hyperviscosity syndrome with transient abnormal myelopoiesis in Down syndrome. Journal of Pediatrics, 112, 58-61.
47. Nijhawan, A., Baselga, E., Gonzalez-Ensenet, M.A., Vincente, A., Southern, J.F., Camitta, B.M., Esterly, N.B. & Drolet, B.A. (2001) Vesiculopustular eruptions in Down syndrome neonates with myeloproliferative disorders. Archives of Dermatology, 137, 760-763.
48. Pevny, L., Lin, C.S., D'Agati, V., Simon, M.C., Orkin, S.H. & Constantini, F. (1995) Development of hematopoietic cells lacking transcription factor GATA-1. Development, 121, 163-172.
49. Pine, S.R., Guo, Q., Yin, C., Jayabose, S., Druschel, C.M. & Sandoval, C. (2007) Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome. Blood, 110, 2128-2131.
50. Polski, J.M., Galambos, C., Gale, G.B., Dunphy, C.H., Evans, H.L. & Batanian, J.R. (2002) Acute megakaryoblastic leukemia after transient myeloproliferative disorder with clonal karyotype evolution in a phenotypically normal neonate. Journal of Pediatric Hematology/Oncology, 24, 50-54.
51. Rankin, J., Tennant, P.W.G., Bythell, M. & Pearce, M.S. (2012) Predictors of survival in children born with Down syndrome: a registry-based study. Pediatrics, 129, e1373-e1381.
52. Robertson, M., De Jong, G. & Mansvelt, E. (2003) Prenatal diagnosis of congenital leukemia in a fetus at 25 weeks' gestation with Down syndrome: case report and review of the literature. Ultrasound in Obstetrics & Gynecology, 21, 486-489.
53. Rosner, F. & Lee, S.L. (1972) Down's syndrome and acute leukemia: myeloblastic or lymphoblastic? American Journal of Medicine, 53, 203-218.
54. Ross, J.D., Moloney, W.C. & Desforges, J.F. (1963) Ineffective regulation of granulopoiesis masquerading as congenital leukemia in a mongoloid child. Journal of Pediatrics, 63, 1-10.
55. Roy, A., Roberts, I., Norton, A. & Vyas, P. (2009) Acute megakaryoblastic leukaemia (AMKL) and transient myeloproliferative disorder (TMD) in Down syndrome: a multi-step model of myeloid leukaemogenesis. British Journal of Haematology, 147, 3-12.
56. Ruchelli, E.D., Uri, A., Dimmick, J.E., Bove, K.E., Huff, D.S., Duncan, L.M., Jennings, J.B. & Witzleben, C.L. (1991) Severe perinatal liver disease and Down syndrome: an apparent relationship. Human Pathology, 22, 1274-1280.
57. Schunk, G.J. & Lehman, W.L. (1954) Mongolism and congenital leukemia. Journal of the American Medical Association, 155, 250-251.
58. Shimizu, R., Takahashi, S., Ohneda, K., Engel, J.D. & Yamamoto, M. (2001) In vivo requirements for GATA-1 functional domains during primitive and definitive erythropoiesis. EMBO Journal, 20, 5250-5260.
59. Shivdasani, R.A., Fujiwara, Y., McDevitt, M.A. & Orkin, S.H. (1997) A lineage selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. EMBO Journal, 16, 3965.
60. Solky, B.A., Yang, F.C., Xu, X. & Levins, P. (2004) Transient myeloproliferative disorder causing a vesiculopustular eruption in a phenotypically normal neonate. Pediatric Dermatology, 21, 551-554.
61. Sorrell, A.D., Alonzo, T.A., Hilden, J.M., Gerbing, R.B., Loew, T.W., Hathaway, L., Barnard, D., Taub, J.W., Ravindranath, Y., Smith, F.O., Arceci, R.J., Woods, W.G. & Gamis, A.S. (2012) Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971. Cancer, published on line March 5, 2012.
62. Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., Theile, J. & Vardiman, J.W. (Eds) (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC, Lyon.
63. Takahashi, S., Komeno, T., Suwabe, N., Yoh, K., Nakajima, O., Nishimura, S., Kuroha, T., Nagasawa, T. & Yamamoto, M. (1998) Role of GATA-1 in proliferation and differentiation of definitive erythroid and megakaryocytic cells in vivo. Blood, 92, 434-442.
64. Tunstall-Pedoe, O., Roy, A., Karadimitris, A., de la Fuente, J., Fisk, N.M., Bennett, P., Norton, A., Vyas, P. & Roberts, I. (2008) Abnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations. Blood, 112, 4507-4511.
65. Vyas, P. & Crispino, J.D. (2007) Molecular insights into Down syndrome-associated leukemia. Current Opinion in Pediatrics, 19, 9-14.
66. Vyas, P., Ault, K., Jackson, C.W., Orkin, S.H. & Shivdasani, R.A. (1999) Consequences of GATA-1 deficiency in megakaryocytes and platelets. Blood, 93, 2867-2875.
67. Wechsler, J., Greene, M., McDevitt, M.A., Anastasi, J., Karp, J.E., Le Beau, M.M. & Crispino, J.D. (2002) Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nature Genetics, 32, 148-152.
68. Weijerman, M.E., van Furth, M., Noordegraaf, A.V., van Wouwe, J.P., Broers, C.J.M. & Gemke, R.J.B.J. (2008) Prevalence, neonatal characteristics, and first-year mortality of Down syndrome: a national study. Journal of Pediatrics, 152, 15-19.
69. Weinberg, A.G., Schiller, G. & Windmiller, J. (1982) Neonatal leukemoid reaction - an isolated manifestation of mosaic trisomy 21. American Journal of Diseases in Childhood, 136, 310-311.
70. Wolfe, L.C., Weinstein, H.J. & Ferry, J.A. (2003) Case 19-2003: a five-day old girl with leukocytosis and a worsening rash from birth. New England Journal of Medicine, 348, 2557-2566.
71. Zerres, K., Schwanitz, G., Niesen, M., Gembruch, U., Hansmann, M. & Waldherr, R. (1990) Prenatal diagnosis of acute non-lymphoblastic leukaemia in Down syndrome. Lancet, 335, 117.
72. Zipursky, A. (2003) Transient leukaemia - a benign form of leukaemia in newborn infants with trisomy 21. British Journal of Haematology, 120, 930-938.
73. Zipursky, A., Peeters, M. & Poon, A. (1987) Megakaryoblastic leukemia and Down's syndrome: a review. Pediatric Hematology and Oncology, 4, 211-230.
74. Zipursky, A., Poon, A. & Doyle, J. (1992) Leukemia in Down syndrome: a review. Pediatric Hematology and Oncology, 9, 139-149.
75. Zipursky, A., Rose, T., Skidmore, M., Thorner, P. & Doyle, J. (1996) Hydrops fetalis and neonatal leukemia in Down syndrome. Pediatric Hematology and Oncology, 13, 81-87.
76. Zipursky, A., Brown, E., Christensen, H., Sutherland, R. & Doyle, J. (1997) Leukemia and/or myeloproliferative syndrome in neonates with Down syndrome. Seminars in Perinatology, 21, 97-101.